GMP News and Research

RSS

Experimental vaccine effective at preventing pneumonia in COVID-19-infected mice

An experimental vaccine is effective at preventing pneumonia in mice infected with the COVID-19 virus, according to a study from Washington University School of Medicine in St. Louis.

12 Aug 2020

New MET ONE 3400+ air particle counter automates routine environmental monitoring for GMP cleanroom compliance

Beckman Coulter Life Sciences announced today that the MET ONE 3400+ portable air particle counter is now available to help GMP cleanroom users simplify their routine environmental monitoring and improve data integrity.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 14 Jul 2020

Oxidized charcoal nanoparticles can help treat COVID-19 patients

Artificial enzymes made of treated charcoal could have the power to curtail damaging levels of superoxides, radical oxygen ions that are toxic at high concentrations.

2 Jul 2020

ACTIV group assesses controlled human infection models for developing SARS-CoV-2 vaccine

In a Perspective for the New England Journal of Medicine, members of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assess practical considerations and prerequisites for using controlled human infection models (CHIMs), which can be used for human challenge studies, to support SARS-CoV-2 vaccine development.

2 Jul 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020

Japanese health supplement could help tackle Covid-19 in people with comorbid conditions

A unique Beta 1,3-1,6 Glucan based Japanese health supplement, produced by black yeast, Aureobasidium Pullulans, could strategically help tackle Covid-19 in people with comorbid conditions like diabetes, kidney and heart diseases, as published in Frontiers in Immunology Journal recommending clinical studies, for validation.

18 Jun 2020

Cobra and AstraZeneca sign supply agreement for manufacture of COVID-19 vaccine candidate

Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

From AstraZeneca 17 Jun 2020

NIAID and Moderna scientists describe SARS-CoV-2 vaccine development

Researchers at the National Institute of Allergy and Infectious Diseases and Moderna Inc., have described the potent neutralizing effects of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is currently being tested in a phase II trial.

14 Jun 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

New biodegradable antiviral filters developed for protective masks

The CSIC's associated unit in Polymer Technology in Castellón will study the biodegradation levels of the materials developed.

18 May 2020

Ori Biotech and CellGenix to collaborate in order to promote innovation within closed-system cell and gene therapy manufacturing

Ori Biotech Ltd announced a partnership to achieve closed-system preparation and the addition of CellGenix media and growth factors within CGT manufacturing.

14 May 2020

Study explores whether senicapoc drug can mitigate lung damage in COVID-19 patients

Scientists around the globe are working to identify approved and investigational drugs that can be repurposed to treat COVID-19.

13 May 2020

Evonik introduces 3D-printable PEEK for medical applications

Evonik is the first company in the world to launch a 3D-printable PEEK (polyether ether ketone) filament as an implant-grade material for medical applications.

7 May 2020

OXGENE™ reports third consecutive year of 100% year on year revenue growth

OXGENE™ has more than doubled its annual revenue in the financial year just closed, in the third consecutive year of 100% year on year revenue growth.

From OXGENE 6 May 2020

USask's VIDO-Intervac receives $23 million to fast-track development of COVID-19 vaccine

The University of Saskatchewan's VIDO-InterVac (Vaccine and Infectious Disease Organization-International Vaccine Centre) has been awarded $23 million to fast-track efforts to develop a COVID-19 vaccine, Prime Minister Justin Trudeau announced today.

24 Apr 2020

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

FDB announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies.

From OXGENE 23 Apr 2020

Review investigates stem cell therapy as potential new treatment for preeclampsia

Preeclampsia is the leading cause of death and disability, for both mothers and babies, killing approximately 76,000 mothers and 500,000 babies globally every year. Despite this, the only cure at present is to deliver the placenta and the baby, with the potential for long term complications.

16 Apr 2020

Microneedle patches for potential COVID-19 vaccines or therapeutics

The COVID-19 pandemic is spreading over the world, causing panic and illness on a scale unprecedented in one hundred years. Even while the death toll nears 100,000, with over 1.5 million confirmed cases worldwide, public health experts and medical professionals are battling it using all the weapons available. Unfortunately, these are all too few.

9 Apr 2020

Cobra Biologics and Karolinska Institutet join forces to develop DNA vaccine against COVID-19

Cobra Biologics, an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet, one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic.

31 Mar 2020

Scientists track down a potential target for new sleeping sickness drugs

Using ultra-bright X-ray flashes, a team of researchers has tracked down a potential target for new drugs against sleeping sickness: The scientists have decoded the detailed spatial structure of a vital enzyme of the pathogen, the parasite Trypanosoma brucei.

30 Jan 2020